WO2007144674A1 - INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS - Google Patents

INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS Download PDF

Info

Publication number
WO2007144674A1
WO2007144674A1 PCT/HU2007/000045 HU2007000045W WO2007144674A1 WO 2007144674 A1 WO2007144674 A1 WO 2007144674A1 HU 2007000045 W HU2007000045 W HU 2007000045W WO 2007144674 A1 WO2007144674 A1 WO 2007144674A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
ethylene
dioxy
norpregna
diene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2007/000045
Other languages
French (fr)
Inventor
Lajosné DANCSI
György Visky
Zoltán Tuba
János CSÖRGEI
Csaba MOLNÁR
Endréné MAGYARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/303,160 priority Critical patent/US8110691B2/en
Priority to AU2007258955A priority patent/AU2007258955B2/en
Priority to PL07733862T priority patent/PL2027140T3/en
Priority to CA2653552A priority patent/CA2653552C/en
Priority to SI200731232T priority patent/SI2027140T1/en
Priority to CN2007800219159A priority patent/CN101466723B/en
Priority to DK07733862.2T priority patent/DK2027140T3/en
Priority to BRPI0713157-7A priority patent/BRPI0713157A2/en
Priority to EA200900015A priority patent/EA015302B1/en
Priority to JP2009514916A priority patent/JP5274453B2/en
Priority to RS20130179A priority patent/RS52758B/en
Priority to ES07733862T priority patent/ES2409841T3/en
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to EP07733862A priority patent/EP2027140B1/en
Priority to MX2008015972A priority patent/MX2008015972A/en
Publication of WO2007144674A1 publication Critical patent/WO2007144674A1/en
Priority to IL195253A priority patent/IL195253A/en
Anticipated expiration legal-status Critical
Priority to NO20090196A priority patent/NO341620B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Definitions

  • the present invention relates to a new industrial process for the synthesis of solvate- free 17 ⁇ -acetoxy-ll ⁇ -[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent.
  • the invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process.
  • the names of the compounds of formulas of Roman numerals on the attached scheme are given in the description of the process according to the invention.
  • the process according to the invention is the following: i) 3-(ethylene-dioxy)-estra-5(10),9(ll)-diene-17-one of formula (X) is reacted with potassium acetilyde formed in situ in dry tetrahydrof ⁇ ran by known method, ii) the obtained 3-(ethylene-dioxy)-17 ⁇ -ethynyl-17 ⁇ -hydroxy-estra-5(10),9(ll)-diene of formula (IX) is reacted with phenylsulfenyl chloride in dichloromethane in the presence of triethylamine and acetic acid, iii) the obtained isomeric mixture of 3-(ethylene-dioxy)-21-(phenyl-sulfinyl)-19- norpregna-5(10),9(ll),17(20),20-tetraene of formula (VIII) is
  • the 4,9-diene structure is formed with pyridinium tribromide to furnish 17 ⁇ ,20 ⁇ -dihydroxy-19-norpregna-4,9-diene-3-one, which is oxidized with oxalyl chloride to yield 17 ⁇ -hydroxy-19-norpregna-4,9-diene-3,20-dione.
  • the pregnane side-chain is synthesized by the so-called SNAP method, which is described in the following publication: J. Am. Chem. Soc, 112, 6449-6450 (1990).
  • the starting material of the synthesis is 3,3-(ethylene-dioxy)- norandrosta-5(10),9(ll)-diene-17-one, which is first transformed into 17 ⁇ -hydroxy,17 ⁇ - cyanhydrine.
  • 17 ⁇ -Hydroxy-19-norpregna-4,9- diene-3,20-dione is transformed without further purification into 3,3,20,20-bis(ethylene- dioxy)-17 ⁇ -hydroxy-19-norpregna-5(10),9(ll)-diene by reacting with ethylene glycol and trimethyl orthoformate in the presence of catalytic amount of p-toluenesulfonic acid.
  • the following reaction step is the oxidation of the 5(10)-double bond with 30% hydrogen peroxide in the presence of hexafluoroacetone and disodium phosphate to epoxide.
  • the total yield of the synthesis is 13%.
  • the patent application WO 2004/078709 describes the following modification of the above process: from 17 ⁇ -hydroxy-19-norpregna-4,9-diene obtained according to the method mentioned above first the 17 ⁇ -acetoxy derivative is synthesized by reacting with a mixture of acetic acid and trifluoroacetic anhydride. The next step is the formation of ketal from the oxo group in position 3 with ethylene glycol and triethyl orthoformate in the presence of p- toluenesulfonic acid to furnish 3,3-(ethylene-dioxy)-17 ⁇ -acetoxy-19-norpregna-5(10),9(ll)- diene-20-one.
  • the synthesis of the 13-ethyl analogue of compound of formula (I) is described in the following publication: Steroids 63 j 50-57 (1998).
  • the starting material of the synthesis is levonorgestrel (17 ⁇ -ethynyl-17 ⁇ -hydroxy-13-ethyl-gon-4-en-3-one) and the reaction sequence is the following: first the 3,3-(ethylene-dioxy)-ketal is formed, from which the 17 ⁇ -ethynyl- 17 ⁇ -hydroxy-13-ethyl-gona-4,9-diene-3-one is synthesized with piridinium tribromid via the ⁇ 5(10) -derivative.
  • the 17 ⁇ -nitroxy derivative is synthesized followed by reacting it with a mixture of formic acid and dimethylformamide in the presence of mercury acetate to furnish 17 ⁇ -formyloxy-13-ethyl-18,19-dinorpregna-4,9-diene-3,20-dione, which is hydrolyzed with potassium hydrogencarbonate to yield 17 ⁇ -hydroxy-13-ethyl-18,19-dinorpregna-4,9-diene- 3,20-dione and the latter is transformed into 3,3,20,20-bis(ethylene-dioxy) derivative.
  • the 5 further reaction steps in the synthesis of compound of formula (I) are the same as above (epoxide formation, Grignard reaction, hydrolysis of the ketal and acylation).
  • 25 norpregna-5(10),9(ll),17(20),20-tetraene of formula (VIII) can be synthesized starting from 3-(ethylene-dioxy)-17 ⁇ -ethynyl-17 ⁇ -hydroxy-estra-5(10),9(ll)-diene of formula (IX) with phenylsulfenyl chloride in the presence of triethylamine and acetic acid in good yield and at higher temperature, than as it was described in the US patent US 4,041,055 (-7O 0 C).
  • the desired product of formula (I) is synthesized from compound of formula (V) in 4 steps, but isolation of only 2 intermediates is necessary.
  • the process according to our invention can preferably be carried out by reacting the 3- (ethylene-dioxy)-estra-5(10),9(ll)-diene-17-one of formula (X) with potassium acetilyde - formed in situ from potassium fert-butoxide and acetylene — in dry tetrahydrofuran at a temperature between -5 and +5 0 C, preferably between 0 and -2 0 C.
  • the obtained 3- (ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(l l),17(20),20-tetraene of formula (VIII) is reacted first with 0.5 equivalent of sodium methoxide in methanol, then with 1.1 equivalent of trimethyl phosphate at a temperature between 50 and 60 0 C, preferably between 62 and 64 °C.
  • the obtained 3-(ethylene-dioxy)-17 ⁇ -hydroxy-20-methoxy-19- norpregna-5(10),9(ll),20-triene of formula (VII) is hydrolyzed with 0.08 equivalent of hydrogen chloride in methanol at a temperature between 20 and 25 °C.
  • Fig. 1 shows formula (I).
  • Fig. 2 shows formula (II).
  • Fig. 3 shows formula (III).
  • Fig. 4 shows formula (IV).
  • Fig. 5 shows formula (V).
  • Fig. 6 shows formula (VI).
  • Fig. 7 shows formula (VII).
  • Fig. 8 shows formula (VIII).
  • Fig. 9 shows formula (IX).
  • Fig. 10 shows formula (X).
  • Acetic anhydride (73 mL, 0.77 mol) was cooled to -10 0 C and 70 % perchloric acid was added (10.8 mL, 0.124 mol). The so obtained solution was cooled to -30 0 C and the solution of compound of formula (II) - obtained in the previous step - in dichloromethane (100 mL) was added at such rate to keep the temperature between -20 and -30 0 C, then the reaction mixture was stirred at this temperature for 1 h. The mixture was diluted with dichloromethane of 0 0 C (300 mL) and poured into water (400 mL) containing sodium acetate (10.25 g, 0.125 mol).
  • the obtained crystalline suspension was cooled to 0-(-2) °C, stirred for 2 h, the precipitated product was filtered off and dried at 50 0 C to yield 48.33 kg (87 %) of the title compound.
  • the purity of the product was 98 % (according to HPLC).
  • Acetic anhydride (18.9 L, 199 mol) was cooled to -10 °C and 70 % perchloric acid was added (2.8 L, 32.1 mol). The so obtained solution was cooled to -30 0 C and the solution of compound of formula (II) - obtained in the previous step - in dichloromethane (26 L) was added at such rate to keep the temperature between -20 and -30 0 C, then the reaction mixture was stirred at this temperature for 1 h. The mixture was diluted with dichloromethane of 0 0 C (80 L) and poured into water (100 L) containing sodium acetate (2.65 kg, 32.4 mol).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a new industrial process for the synthesis of solvate- free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent. The invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process. The process according to the invention is the following: i) 3-(ethylene-dioxy)-estra-5(10),9(11)-diene-17-one of formula (X) is reacted with potassium acetilyde formed in situ in dry tetrahydrofuran by known method, ii) the obtained 3-(ethylene-dioxy)-17α-ethynyl-17β-hydroxy-estra-5(10),9(11)-diene of formula (IX) is reacted with phenylsulfenyl chloride in dichloromethane in the presence of triethylamine and acetic acid, iii) the obtained isomeric mixture of 3-(ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(11),17(20),20-tetraene of formula (VIII) is reacted first with sodium methoxide in methanol, then with trimethyl phosphite, iv) the obtained 3-(ethylene-dioxy)-17α-hydroxy-20-methoxy-19-norpregna-5(10),9(11),20-triene of formula (VII) is reacted with hydrogen chloride in methanol, then v) the obtained 3-(ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(11l)-diene-20- one of formula (VI) is reacted with ethylene glycol hi dichloromethane in the presence of trimethyl orthoformate and p-toluenesulfonic acid by known method, vi) the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-19-norpregna- 5(10),9(11)-diene of formula (V) is reacted with hydrogen peroxide in a mixture of pyridine and dichloromethane in the presence of hexachloroacetone by known method, vii) the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-5,10-epoxy-19-norpregn-9(11)-ene of formula (IV), containing approximately a 1:1 mixture of 5α,10α- and 5β,10β-epoxides, is isolated from the solution and reacted with a Grignard reagent obtained from 4-bromo-N,N-dimethyl-aniline in tetrahydrofuran in the presence of copper(I) chloride catalyst without separation of the isomers by known method, viii) the obtained 3,3,20,20-bis(ethylene-dioxy)-5α,17α-dihydroxy-11β-[4-(N,N-dimethylamino)-phenyl]-19-norpregn-9(11)-ene of formula (III) is reacted with potassium hydrogensulfate in water by known method, ix) the obtained 11β-[4-(N,N-dimethylamino)-phenyl]-17α-hydroxy-19-norpregn-4,9-diene-3,20-dione of formula (II) is acetylated with acetic anhydride in the presence of perchloric acid by known method, finally x) the solvate-free compound of formula (I) is liberated from the obtained solvate containing compound of formula (I) in a 1 : 1 mixture of ethanol and water at 70° C.

Description

Industrial process for the synthesis of 17α-acetoxy-llβ44-(N,N-dimethyI-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
The present invention relates to a new industrial process for the synthesis of solvate- free 17α-acetoxy-llβ-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent.
The invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process.
The names of the compounds of formulas of Roman numerals on the attached scheme are given in the description of the process according to the invention. The process according to the invention is the following: i) 3-(ethylene-dioxy)-estra-5(10),9(ll)-diene-17-one of formula (X) is reacted with potassium acetilyde formed in situ in dry tetrahydrofαran by known method, ii) the obtained 3-(ethylene-dioxy)-17α-ethynyl-17β-hydroxy-estra-5(10),9(ll)-diene of formula (IX) is reacted with phenylsulfenyl chloride in dichloromethane in the presence of triethylamine and acetic acid, iii) the obtained isomeric mixture of 3-(ethylene-dioxy)-21-(phenyl-sulfinyl)-19- norpregna-5(10),9(ll),17(20),20-tetraene of formula (VIII) is reacted first with sodium methoxide in methanol, then with trimethyl phosphite, iv) the obtained 3-(ethylene-dioxy)-17α-hydroxy-20-methoxy-19-norpregna- 5(10),9(l l),20-triene of formula (VII) is reacted with hydrogen chloride in methanol, then v) the obtained 3-(ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)-diene-20- one of formula (VI) is reacted with ethylene glycol in dichloromethane in the presence of trimethyl orthoformate and p-toluenesulfonic acid by known method, vi) the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-19-norpregna- 5(10),9(ll)-diene of formula (V) is reacted with hydrogen peroxide in a mixture of pyridine and dichloromethane in the presence of hexachloroacetone by known method, vii) the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-5,10-epoxy-19-norpregn-
9(ll)-ene of formula (IV), containing approximately a 1:1 mixture of 5α,10α- and 5β,10β- epoxides, is isolated from the solution and reacted with a Grignard reagent obtained from 4- bromo-N,N-dimethyl-aniline in tetrahydrofuran in the presence of copper(I) chloride catalyst without separation of the isomers by known method, viii) the obtained 3,3,20,20-bis(ethylene-dioxy)-5α,17α-dihydroxy-llβ-[4-(N,N- dimethylamino)-phenyl]-19-norpregn-9(ll)-ene of formula (III) is reacted with potassium hydrogensulfate in water by known method, ix) the obtained llβ-[4-(N,N-dimethylamino)-phenyl]-17α-hydroxy-19-norpregn-4,9- diene-3,20-dione of formula (II) is acetylated with acetic anhydride in the presence of perchloric acid by known method, finally x) the solvate-free compound of formula (I) is liberated from the obtained solvate containing compound of formula (I) in a 1:1 mixture of ethanol and water at 70 °C.
The synthesis of compound of formula (I) was first described in the US patent US 4,954,490 starting from 3-methoxy-19-norpregna-l,3,5(10),17(20)-tetraene. First the 17α,20α-diol is synthesized by oxidation of the 17(20)-double bond with osmium tetroxide, which is transformed into 3-methoxy-19-norpregna-2,5(10)-diene-17α,20α-diol by Birch reduction. Then the 4,9-diene structure is formed with pyridinium tribromide to furnish 17α,20α-dihydroxy-19-norpregna-4,9-diene-3-one, which is oxidized with oxalyl chloride to yield 17α-hydroxy-19-norpregna-4,9-diene-3,20-dione. Then the 3,3,20,20-bis(ethylene- dioxy)-19-nor-pregna-5(10),9(ll)-diene-17α-ol is synthesized by ketal formation and the compound is reacted with metha-chloroperbenzoic acid to furnish 5α,10α-epoxy-3,3,20,20- bis(ethylene-dioxy)-19-norpregn-9(ll)-ene-17α-ol. The latter is transformed into 3,3,20,20- bis(ethylene-dioxy)-5α,17α-dihydroxy-llβ-[4-(N,N-dimethylamino)-phenyl]-19-norpregn- 9(ll)-ene by Grignard reaction with p-(N,N-dimethylamino)-phenyl-magnesium bromide in the presence of CuCl catalyst and finally the compound of formula (I) is obtained by acylation with a mixture of acetic anhydride and phosphoric acid. This is a 10-step synthesis, the total yield of which is 0.62%, consequently it is not suitable for industrial production of the active ingredient. According to the US patent US 5,929,262 the pregnane side-chain is synthesized by the so-called SNAP method, which is described in the following publication: J. Am. Chem. Soc, 112, 6449-6450 (1990). The starting material of the synthesis is 3,3-(ethylene-dioxy)- norandrosta-5(10),9(ll)-diene-17-one, which is first transformed into 17α-hydroxy,17β- cyanhydrine. The latter is reacted with chloro-(chlormethyl)-dimethylsilane in the presence of 4-(N,N-dimethylamino)-pyridine to yield 17β-cyano-17α-[(chlormethyl)-dimethylsilyl]-estra- 5(10),9(ll)-diene, which is transformed into 17α-hydroxy-19-norpregna-4,9-diene-3,20-dione by intramolecular addition in the presence of lithium di-fert-butyl-biphenyl followed by reaction of the obtained product with hydrochloric acid. 17α-Hydroxy-19-norpregna-4,9- diene-3,20-dione is transformed without further purification into 3,3,20,20-bis(ethylene- dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)-diene by reacting with ethylene glycol and trimethyl orthoformate in the presence of catalytic amount of p-toluenesulfonic acid. The following reaction step is the oxidation of the 5(10)-double bond with 30% hydrogen peroxide in the presence of hexafluoroacetone and disodium phosphate to epoxide. Then 3 ,3 ,20,20-bis(ethylene-dioxy)-5α, 17α-dihydroxy- 1 lβ-[4-(N,N-dimethylamino)-phenyl]- 19- norpregn-9-ene is obtained by Grignard reaction with p-(N,N-dimethylamino)-phenyl- magnesium bromide in the presence of CuCl catalyst and compound of formula (I) is synthesized by acylation with trifluoroacetic anhydride and acetic acid in the presence of p- toluenesulfonic acid catalyst, hi the first steps of the 9-step process the applied reagents are hazardous from the point of environmental protection (alkali cyanides and metal lithium are used for the synthesis of cyanhydrine) and the reaction temperature is -70 °C, which is disadvantageous in an industrial production. The total yield of the synthesis is 13%. The patent application WO 2004/078709 describes the following modification of the above process: from 17α-hydroxy-19-norpregna-4,9-diene obtained according to the method mentioned above first the 17α-acetoxy derivative is synthesized by reacting with a mixture of acetic acid and trifluoroacetic anhydride. The next step is the formation of ketal from the oxo group in position 3 with ethylene glycol and triethyl orthoformate in the presence of p- toluenesulfonic acid to furnish 3,3-(ethylene-dioxy)-17α-acetoxy-19-norpregna-5(10),9(ll)- diene-20-one. This is transformed into 5α,10α-epoxide derivative with 30 % hydrogen peroxide in the presence of hexafluoroacetone and disodium hydrogenphosphate and the 5α- hydroxy-17α-acetoxy-3,3-(ethylene-dioxy)-llβ-[4-(N,N-dimethylamino)-phenyl]-19- norpregn-9(10)-ene-20-one is obtained by Grignard reaction using only 2 equivalent of the reagent in contrary to the above mentioned processes. The final product of formula (I) is obtained by hydrolysis with aqueous acetic acid.
The synthesis of the 13-ethyl analogue of compound of formula (I) is described in the following publication: Steroids 63j 50-57 (1998). The starting material of the synthesis is levonorgestrel (17α-ethynyl-17β-hydroxy-13-ethyl-gon-4-en-3-one) and the reaction sequence is the following: first the 3,3-(ethylene-dioxy)-ketal is formed, from which the 17α-ethynyl- 17β-hydroxy-13-ethyl-gona-4,9-diene-3-one is synthesized with piridinium tribromid via the Δ5(10)-derivative. Then the 17β-nitroxy derivative is synthesized followed by reacting it with a mixture of formic acid and dimethylformamide in the presence of mercury acetate to furnish 17α-formyloxy-13-ethyl-18,19-dinorpregna-4,9-diene-3,20-dione, which is hydrolyzed with potassium hydrogencarbonate to yield 17α-hydroxy-13-ethyl-18,19-dinorpregna-4,9-diene- 3,20-dione and the latter is transformed into 3,3,20,20-bis(ethylene-dioxy) derivative. The 5 further reaction steps in the synthesis of compound of formula (I) are the same as above (epoxide formation, Grignard reaction, hydrolysis of the ketal and acylation). The yield of the synthesis of 17β-nitroxy derivative and the formation of the side-chain is 29%, the total yield of the synthesis is 3.5%. Further disadvantage of the process is that the intermediates of the synthesis are purified by column chromatography, which is very expensive on industrial scale.
- -10 In the following publication: Bioorg. Med. Chem. Lett., 1997, 2229-2234, the synthesis of the 17α-ethynyl derivative and from this the 5α,10α-epoxide is described starting from 3,3-(ethylene-dioxy)-19-norandrosta-5(10),9(ll)-diene-17-one - which is used as starting material in the process of our invention as well.
A process for the synthesis of pregnane side-chain - in the series of corticoids - is
15 described in the US patent US 4,041,055 according to which the 21-(phenylsulfinyl)-pregnane derivative is obtained from the 17α-ethynyl-androstane derivative with phenylsulfenyl chloride in the presence of triethylamine, followed by Michael addition to furnish 20- methoxy-21-(phenylsulfinyl) derivative. The latter is reacted with trimethyl phosphite to yield the 17α-hydroxy-20-keto-pregnane derivative and the 17α-hydroxy-20-keto-pregnane is
20 obtained by acid hydrolysis.
It is known that 3-(ethylene-dioxy)-17α-ethynyl-17β-hydroxy-estra-5(10),9(ll)-diene of formula (IX) can be synthesized from 3-(ethylene-dioxy)-estra-5(10),9(l l)-diene-17-one of
— formula (X), which is an industrial product readily available in large quantities. The basis of our invention is the discovery that the new 3-(ethylene-dioxy)-21-(phenylsulfinyl)-19-
25 norpregna-5(10),9(ll),17(20),20-tetraene of formula (VIII) can be synthesized starting from 3-(ethylene-dioxy)-17α-ethynyl-17β-hydroxy-estra-5(10),9(ll)-diene of formula (IX) with phenylsulfenyl chloride in the presence of triethylamine and acetic acid in good yield and at higher temperature, than as it was described in the US patent US 4,041,055 (-7O0C). The new 3-(ethylene-dioxy)-17α-hydroxy-20-methoxy-19-norpregna-5(10),9(l l),20-triene of formula
30 (VII) can be obtained from compound of formula (VIII) by addition of methanol followed by reaction with trimethyl phosphite. The new 3-(ethylene-dioxy)-17α-hydroxy-19-norpregna- 5(10),9(ll)-diene-20-one of formula (VI) is synthesized from the 20-methoxy derivative by hydrolysis with hydrochloric acid. The known 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy- 19-norpregna-5(10),9(ll)-diene of formula (V) is obtained from compound of formula (VI) in a ketal formation reaction with ethylene glycol in the presence of trimethyl orthoformate and p-toluenesulfonic acid. The desired product of formula (I) is synthesized from compound of formula (V) in 4 steps, but isolation of only 2 intermediates is necessary. First the 5α,10α- epoxide of formula (IV) is synthesized, then this is transformed into 5α-hydroxy-ll-[4-(N,N- dimethylamino)-phenyl] derivative of formula (III) by Grignard reaction in the presence of CuCl catalyst. After acid hydrolysis the 17α-hydroxy-llβ-[4-(N,N-dimethyl-amino)-phenyl]- pregna-4,9-diene-3,20-dione of formula (II) is obtained and the latter is acylated with a mixture of acetic anhydride perchloric acid to yield the desired compound of formula (I), which is transformed into solvate-free form.
The process according to our invention can preferably be carried out by reacting the 3- (ethylene-dioxy)-estra-5(10),9(ll)-diene-17-one of formula (X) with potassium acetilyde - formed in situ from potassium fert-butoxide and acetylene — in dry tetrahydrofuran at a temperature between -5 and +5 0C, preferably between 0 and -2 0C. The obtained 3-(ethylene- dioxy)-17α-ethynyl-17β-hydroxy-estra-5(10),9(ll)-diene of formula (IX) is reacted in a dichloromethane solution with a solution of 1.3 equivalent of phenylsulfenyl chloride in chloroform at a temperature between -10 and +5 0C, preferably between 0 and -5 °C, in the presence of 1.3 equivalent of triethylamine and 1.2 equivalent of acetic acid. The obtained 3- (ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(l l),17(20),20-tetraene of formula (VIII) is reacted first with 0.5 equivalent of sodium methoxide in methanol, then with 1.1 equivalent of trimethyl phosphate at a temperature between 50 and 60 0C, preferably between 62 and 64 °C. The obtained 3-(ethylene-dioxy)-17α-hydroxy-20-methoxy-19- norpregna-5(10),9(ll),20-triene of formula (VII) is hydrolyzed with 0.08 equivalent of hydrogen chloride in methanol at a temperature between 20 and 25 °C. The obtained 3- (ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)-diene-20-one of formula (VI) is reacted with 10 equivalent of ethylene glycol and 6 equivalent of trimethyl orthoformate in dichloromethane in the presence and p-toluenesulfonic acid at a temperature between 20 and 25 0C. The obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)- diene of formula (V) is reacted with 5 equivalent of 50% hydrogen peroxide solution in a mixture of pyridine and dichloromethane in the presence of 0.25 equivalent of hexachloroacetone at a temperature between -10 and +10 0C, preferably between 0 and -2 °C. The obtained 3,3,20,20-bis(emylene-dioxy)-17α-hydroxy-5,10-epoxy-19-norpregn-9(l l)-ene of formula (IV), containing a 55:45 mixture of 5α,10α- and 5β,10β-epoxides, is reacted in the next step without purification and separation of the isomers. The mixture of epoxides of formula (IV) is reacted with 5 equivalent of 4-(N,N-dimethylamino)-phenyl magnesium bromide - obtained from 4-bromo-N,N-dimethyl-aniline and magnesium - in tetrahydrofuran in the presence of CuCl catalyst at a temperature between 15 and 20 °C. The obtained 3,3,20,20-bis(ethylene-dioxy)-5α,17α-dihydroxy-llβ-[4-(N,N-dimethylamino)-phenyl]-19- norpregn-9(ll)-ene of formula (III) is reacted with 2.5 equivalent of potassium hydrogensulfate in water at a temperature between 0 and 5 0C, then the reaction mixture is extracted with dichloromethane. The obtained solution of llβ-[4-(N,N-dimethylamino)- phenyl]-17α-hydroxy-19-norpregn-4,9-diene-3,20-dione of formula (II) in dichloromethane is directly used in the final step of the synthesis, in the acylation of 17-hydroxy group. The solution of compound of formula (II) is reacted with 10 equivalent of acetic anhydride in the presence of 1.5 equivalent of 70% perchloric acid at a temperature between -10 and -40 °C, preferably between -25 and -30 0C for 1 h. The obtained crude 17α-acetoxy-llβ-[4-(N,N- dimethylamino)-phenyl]-19-norpregna-4,9-diene-3,20-dione of formula (I) is recrystallized from isopropanol, then solvate-free compound is liberated from the obtained solvate containing compound of formula (I) in a 1:1 mixture of ethanol and water. The advantages of our invention are the following: 1) It can be carried out on industrial scale using commercially available starting material.
2) It is a 9-step process, but only the isolation of 7 intermediates is necessary.
3) A new process is applied in the series of norsteroids using phenylsulfenyl chloride in the synthesis of the side-chain. From the point of industrial applicability the advantage of this is that the reaction is carried out via the new intermediates of formulas (VIII) and (VII) at a temperature between 0 and -5 0C, instead of -70 0C used in the synthesis of analogous compounds according to the literature.
4) It is not necessary to separate the isomeric mixture of 5α,10α- and 5β,10β-epoxides of compound of formula (IV) as the by-products formed during the synthesis can easily be separated in the next step. 5) The solvate-free product is obtained in a less dangerous solvent, a 1:1 mixture of ethanol and water at 70 °C, than the flammable, explosive, industrially not applicable diethyl ether - the use of which is described in the literature.
Fig. 1 shows formula (I). Fig. 2 shows formula (II). Fig. 3 shows formula (III). Fig. 4 shows formula (IV). Fig. 5 shows formula (V). Fig. 6 shows formula (VI). Fig. 7 shows formula (VII). Fig. 8 shows formula (VIII). Fig. 9 shows formula (IX). Fig. 10 shows formula (X).
The process according to our invention is illustrated by the following not limiting examples.
Example 1 3-(EthvIene-dioxy)-17α-ethvnyl-17β-hvdroxy-estra-5(10),9(ll)-diene (IX)
Under nitrogen potassium tert-butoxide (60 g) was dissolved in dry tetrahydrofuran (1500 mL) and acetylene was bubbled to the solution at 20 °C for 30 min, then the solution was cooled to 0-(-2) °C and bubbling of the acetylene was continued for a further 30 min. Then compound of formula (X) (119.4 g, 0.38 mol) was added while bubbling of the acetylene was continued. The reaction mixture was stirred for 1 h and nitrogen was bubbled through the mixture in order to remove the excess of acetylene. Saturated ammonium chloride solution (750 mL) was added and the reaction mixture was stirred for 10 min. The organic layer was separated and the water phase was extracted with tetrahydrofuran (300 mL). The combined organic layers were washed with saturated ammonium chloride solution (150 mL), concentrated to a volume of 600 mL and poured into ice- water (4 L). The obtained mixture was stirred for 30 min, the precipitated crystalline product was filtered off and dried at 40 0C to yield 122.8 g (95 %) of the title compound. The purity of the product was min. 95 % (according to HPLC). Example 2
3-(Ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(ll)α7(20),20-tetraene (VIII)
To a suspension of compound of formula (IX) (122.5 g, 0.36 mol), triethylamine (151 mL) and acetic acid (24.6 mL) in dichloromethane (2200 mL) a solution of phenylsulfenyl chloride (67.9 g, 0.47 mol) in chloroform (170 mL) was added dropwise while keeping the temperature between 0 and -5 0C. The reaction mixture was stirred for 10 min, then water (250 mL) and methanol (100 mL) was added. The organic layer was separated, washed with IN hydrochloric acid and water, dried over sodium sulfate and concentrated to a volume of 185 mL. Diisopropyl ether (120 mL) was added to the residue and mixture was cooled to 5 °C. The precipitated crystals were filtered off and dried below 60 0C to yield 144 g (88 %) of the title compound. The purity of the product was min. 95 % (according to HPLC).
Melting point: 176-180 0C. Example 3 3-(Ethylene-dioxy)-17α-hvdroxy-20-methoxy-19-norpregna-5αθ),9(ll),20-triene (VII)
To a solution of sodium methoxide (8.67 g, 0.16 mol) in methanol (4320 mL) compound of formula (VIII) (144 g, 0.321 mol) was added. The reaction mixture was stirred at 62-64 °C for 3 h, then trimethyl phosphite (42 mL, 0.35 mol) was added and stirring was continued at 62-64 0C for 2 h. The reaction mixture was cooled to 20 °C and poured into a solution of sodium chloride (288 g) in water (14 L). The precipitated crystalline product was filtered off, washed with water and dried at 40 0C to yield 80.2 g (67 %) of the title compound. The purity of the product was min. 95 % (according to HPLC).
Melting point: 128-132 0C. Example 4 3-(EthvIene-dioxy)-17α-hvdroxy-19-norpregna-5(10),9qi)-diene-20-one (VI)
A suspension of compound of formula (VII) (80 g, 0.27 mol) in a mixture of IN hydrochloric acid (18 mL) and methanol (800 mL) was stirred at 20-25 0C for 40 min, then water of 10 °C (800 mL) was added and the reaction mixture was stirred for 30 min. The precipitated crystalline product was filtered off, washed with water and dried at 60 0C to yield 73 g (95 %) of the title compound. The purity of the product was 98 % (according to HPLC). Melting point: 140-140 0C. Example 5
3,3,20,20-Bis(ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)-diene (V)
To a solution of compound of formula (VI) (73 g, 0.2 mol) in dichloromethane (580 mL) ethylene glycol (126 mL, 2.26 mol), trimethyl orthoformate (132 mL, 1.21 mol) and p- toluenesulfonic acid (4.85 g) were added. The reaction mixture was stirred at 20-25 0C for 2 h, then saturated sodium hydrogencarbonate solution (380 mL) was added and stirring was continued for 30 min. The organic layer was separated, washed with water (400 mL), dried over sodium sulfate and concentrated to a volume of 175 mL. Methanol (230 mL) containing 0.5 % pyridine was added and the solution was concentrated to a volume of 175 mL in order to remove dichloromethane. The obtained crystalline suspension was cooled to 0-2 0C, stirred for 2 h, the precipitated product was filtered off and dried at 50 0C to yield 71.5 g (87 %) of the title compound. The purity of the product was 98 % (according to HPLC).
Melting point: 112-11 A °C. Example 6 3,3,20,20-Bis(ethylene-dioxy)-17α-hydroxy-5α,10α-epoxy-19-norpregn-9(ll)-ene (IV) Under nitrogen to a solution of compound of formula (V) (71 g, 0.176 mol) in dichloromethane (360 mL) and pyridine (1.8 mL) hexachloroacetone (6.5 mL, 0.043 mol) and 50 % hydrogen peroxide solution (51.5 mL, 0.9 mol) were added at 0-(-2) 0C and the reaction mixture was stirred at 0-2 0C for 3 h. Then dichloromethane (1800 mL) and ice- water (1440 mL) containing sodium thiosulfate (160 g) were added and the mixture was stirred at 0-10 °C for 30 min. The organic layer was separated, washed with water (300 mL), dried over sodium sulfate and concentrated under reduced pressure to yield 83 g of product, which is a 55:45 mixture of the 5α,10α- and 5β,10β-epoxides. The obtained crude mixture of epoxides was used in the next step without further purification. Example 7
3,3,20,20-Bis(ethylene-dioxy)-5αl7α-dihvdroxy-llβ-r4-(N,N-dimethylamino)-phenvn-19- norpregn-9(ll)-ene (III) A mixture of magnesium turnings (23.3 g, 0.97 mol) and 1,2-dibromoethane (0.35 mL) in tetrahydrofuran (44 mL) was stirred at 40-50 0C for 5 min, then the reaction mixture was cooled to 15 °C and a solution of 4-bromo-N,N-dimethylaniline (176 g, 0.88 mol) in tetrahydrofurane (1050 mL) was added at such a rate to keep the temperature below 15 °C. Then the reaction mixture was stirred at 16-18 °C for 2 h to obtain the solution of the Grignard reagent.
The mixture of the epoxides (74 g, 0.176 mol) - obtained in the previous step - was dissolved in dichloromethane (300 mL) and copper(I) chloride (4 g) was added. The reaction mixture was stirred at 20-25 0C for 15 min, then cooled to 15 0C and the solution of the Grignard reagent was added over a period of 45 min. The reaction mixture was stirred at 20- 25 0C for 2 h, then poured into water (1400 mL) containing ammonium chloride (170 g). The organic layer was separated, the water phase was extracted with dichloromethane (2x200 mL), the combined organic layers were washed with water (5x500 mL), dried over sodium sulfate and concentrated. The residue was dissolved in ethyl acetate (200 mL) at reflux temperature, the solution was cooled to -5 °C and the obtained crystalline suspension was kept at this temperature for 5 h. The precipitated product was filtered off and dried at 60 °C to yield 41.7 g (46 %) of the title compound. The purity of the product was min. 95 % (according to HPLC).
Melting point: 228-232 0C. Example 8 llβ-r4-(N,N-dimethylamino)-phenyn-17α-hydroxy-19-norpregna-4,9-diene-3,20-dione
OD To a solution of potassium hydrogensulfate (27.5 g, 0.2 mol) in water (230 mL) compound of formula (III) (41.7 g, 0.077 mol) was added at +5 °C and the reaction mixture was stirred at this temperature for 4 h. Then dichloromethane (230 mL) and a solution of potassium hydroxide (4.3 g) in water (40 mL) were added, the organic layer was separated and dried over sodium sulfate. Silicagel (7.5 g) was added and the dichloromethane solution was stirred at 20-25 0C for 30 min, then filtered. The filtrate was concentrated to a volume of 100 mL and the so obtained solution - containing llβ-[4-(N,N-dimethylamino)-phenyl]-17α- hydroxy-19-norpregna-4,9-diene-3,20-dione - was used in the next step. Example 9 17α-Acetoxy-llβ-r4-(N,N-dimethyIamino)-phenvn-19-norpregna-4,9-diene-3,20-dione
01
Acetic anhydride (73 mL, 0.77 mol) was cooled to -10 0C and 70 % perchloric acid was added (10.8 mL, 0.124 mol). The so obtained solution was cooled to -30 0C and the solution of compound of formula (II) - obtained in the previous step - in dichloromethane (100 mL) was added at such rate to keep the temperature between -20 and -30 0C, then the reaction mixture was stirred at this temperature for 1 h. The mixture was diluted with dichloromethane of 0 0C (300 mL) and poured into water (400 mL) containing sodium acetate (10.25 g, 0.125 mol). The organic layer was separated, washed with water (3x100 mL), dried over sodium sulfate and concentrated under reduced pressure. The obtained yellow syrupy material was crystallized from isopropanol (150 mL) to yield 27 g of the title compound in solvate form, containing 5-10 % solvent. This material was dissolved in ethanol (230 mL) at 60 0C, then warmed to 70 °C and ion-exchanged water (260 mL) was added. Nitrogen was bubbled through the so obtained solution, which was kept at 70 0C for 14 h. The solvate-free crystalline product gradually precipitated from the solution. The crystals were filtered at 70 0C, washed with water of 70 °C and dried at 40 0C to yield 24 g (66 %) of the title compound. The purity of the product was 99 % (according to HPLC).
Melting point: 184-186 °C. Example 10 3-(EthvIene-dioxy)-17α-ethvnvI-17β-hvdroxy-estra-5(10),9αi)-diene qX) Under nitrogen potassium fert-butoxide (22.6 kg) was dissolved in dry tetrahydrofuran
(565 L) and acetylene was bubbled to the solution at 20 0C for 30 min, then the solution was cooled to 0-(-2) 0C and bubbling of the acetylene was continued for a further 30 min. Then compound of formula (X) (45 kg, 143 mol) was added while bubbling of the acetylene was continued. The reaction mixture was stirred for 1 h and nitrogen was bubbled through the mixture in order to remove the excess of acetylene. Saturated ammonium chloride solution (280 L) was added and the reaction mixture was stirred for 20 min. The organic layer was 5 separated and the water phase was extracted with tetrahydrofuran (110 L). The combined organic layers were washed with saturated ammonium chloride solution (55 L), concentrated to a volume of 220 L and poured into ice- water (1500 L). The obtained mixture was stirred for 30 min, the precipitated crystalline product was filtered off and dried at 40 0C to yield 47.4 kg (97.2 %) of the title compound. The purity of the product was min. 95 % (according
10 to HPLC). Example 11
3-(Ethylene-dioxy)-21-(phenvI-suffinyl)-19-norpregna-5(10),9(ll)q7(20),20-tetraene (VIII)
To a suspension of compound of formula (IX) (40 kg, 117 mol), triethylamine (49 L)
15 and acetic acid (8 L) in dichloromethane (720 L) a solution of phenylsulfenyl chloride (22.1 kg, 153 mol) in chloroform (55 L) was added dropwise while keeping the temperature between 0 and -5 0C. The reaction mixture was stirred for 10 min, then water (80 L) and methanol (32 L) was added. The organic layer was separated, washed with IN hydrochloric acid and water, dried over sodium sulfate and concentrated to a volume of 28 L. Diisopropyl
20 ether (40 L) was added to the residue and mixture was cooled to 5 °C. The precipitated crystals were filtered off and dried below 60 0C to yield 45.8 kg (87.3 %) of the title compound. The purity of the product was min. 95 % (according to HPLC).
Melting point: 176-180 0C. Example 12
25 3-(Ethylene-dioxy)-17α-hvdroxy-20-methoxy-19-norpregna-5(10),9(ll),20-triene (VII)
To a solution of sodium methoxide (1.2 kg, 22.2 mol) in methanol (600 L) compound of formula (VIII) (20 kg, 44.6 mol) was added. The reaction mixture was stirred at 62-64 °C for 3 h, then trimethyl phosphite (5.8 L, 48.6 mol) was added and stirring was continued at 62-64 °C for 2 h. The reaction mixture was cooled to 20 °C and poured into a solution of
"30 sodium chloride (40 kg) in water (1940 L). The precipitated crystalline product was filtered off, washed with water and dried at 40 0C to yield 12.5 kg (75.3 %) of the title compound. The purity of the product was min. 95 % (according to HPLC). Melting point: 128-132 °C. Example 13 3-(EthvIene-dioxy)-17α-hvdroxy-19-norpregna-5(10),9(ll)-diene-20-one (VI)
A suspension of compound of formula (VII) (56 kg, 150 mol) in a mixture of IN hydrochloric acid (12.6 L) and methanol (560 L) was stirred at 20-25 0C for 40 min, then water of 10 °C (560 L) was added and the reaction mixture was stirred for 30 min. The precipitated crystalline product was filtered off, washed with water and dried at 60 0C to yield 51.1 kg (95 %) of the title compound. The purity of the product was 98 % (according to HPLC). Melting point: 140-140 0C.
Example 14 3,3,20,20-Bis(ethylene-dioxy)-17α-hvdroxy-19-norpregna-5(10),9(ll)-diene (V)
To a solution of compound of formula (VI) (49.3 kg, 137 mol) in dichloromethane (390 L) ethylene glycol (85 L, 1527 mol), trimethyl orthoformate (89 L, 818 mol) and p- toluenesulfonic acid (3.28 kg) were added. The reaction mixture was stirred at 20-25 °C for 2 h, then saturated sodium hydrogencarbonate solution (260 L) was added and stirring was continued for 30 min. The organic layer was separated, washed with water (270 L), dried over sodium sulfate and concentrated to a volume of 118 L. Methanol (150 L) containing 0.5 % pyridine was added and then evaporated in order to remove dichloromethane. The obtained crystalline suspension was cooled to 0-(-2) °C, stirred for 2 h, the precipitated product was filtered off and dried at 50 0C to yield 48.33 kg (87 %) of the title compound. The purity of the product was 98 % (according to HPLC).
Melting point: 112-11 A 0C. Example 15 3,3,20,20-Bis(ethylene-dioxy)-17α-hvdroxy-5α,10α-epoxy-19-norpregn-9(ll)-ene (IV)
Under nitrogen to a solution of compound of formula (V) (20 kg, 49.7 mol) in dichloromethane (100 L) and pyridine (0.5 L) hexachloroacetone (1.8 L, 12 mol) and 50 % hydrogen peroxide solution (14.5 L, 253 mol) were added at 0-(-2) °C and the reaction mixture was stirred at 0-2 0C for 3 h. Then dichloromethane (500 L) and ice-water (400 L) containing sodium thiosulfate (50 kg) were added and the mixture was stirred at 0-10 °C for 30 mm. The organic layer was separated, washed with water (85 L), dried over sodium sulfate and concentrated under reduced pressure to yield 23.3 kg of product, which is a 55:45 mixture of the 5α,10α- and 5β,10β-epoxides. The obtained crude mixture of epoxides was used in the next step without further purification. Example 16 3,3,20,20-Bis(ethylene-dioxy)-5αl7α-dihvdroxy-llβ-r4-(N,N-dimethvIamino)-phenvn-19- norpregn-9(ll)-ene (HI)
A mixture of magnesium turnings (6.55 kg, 272 mol) and 1,2-dibromoethane (0.1 L) in tetrahydrofuran (13 L) was stirred at 40-50 °C for 5 min, then the reaction mixture was cooled to 15 0C and a solution of 4-bromo-N,N-dimethylaniline (49.5 kg, 247 mol) in tetrahydrofurane (300 L) was added at such a rate to keep the temperature below 15 0C. Then the reaction mixture was stirred at 16-18 0C for 2 h to obtain the solution of the Grignard reagent.
The mixture of the epoxides (20.8 kg, 49.7 mol) - obtained in the previous step - was dissolved in dichloromethane (85 L) and copper(I) chloride (1.12 kg) was added. The reaction mixture was stirred at 20-25 °C for 15 min, then cooled to 15 °C and the solution of the Grignard reagent was added over a period of 45 min. The reaction mixture was stirred at 20- 25 0C for 2 h, then poured into water (400 L) containing ammonium chloride (48 kg). The organic layer was separated, the water phase was extracted with dichloromethane (2x60 L), the combined organic layers were washed with water (5x140 L), dried over sodium sulfate and concentrated. The residue was dissolved in ethyl acetate (60 L) at reflux temperature, the solution was cooled to -5 °C and the obtained crystalline suspension was kept at this temperature for 5 h. The precipitated product was filtered off and dried at 60 0C to yield 12.6 kg (47 %) of the title compound. The purity of the product was min. 95 % (according to HPLC).
Melting point: 228-232 °C. Example 17 llβ-r4-(N,N-dimethylamino)-phenvn-17α-hydroxy-19-norpregna-4,9-diene-3,20-dione on
To a solution of potassium hydrogensulfate (7.12 kg, 51.8 mol) in water (60 L) compound of formula (III) (11.7 kg, 21.7 mol) was added at +5 °C and the reaction mixture was stirred at this temperature for 4 h. Then dichloromethane (60 L) and a solution of potassium hydroxide (1.11 kg) in water (10 L) were added, the organic layer was separated and dried over sodium sulfate. Silicagel (2 kg) was added and the dichloromethane solution was stirred at 20-25 °C for 30 min, then filtered. The filtrate was concentrated to a volume of 26 L and the so obtained solution was used in the next step. Example 18 17α-Acetoxy-llβ-r4-(N,N-dimethyIamino)-phenvn-19-norpregna-4,9-diene-3,20-dione β)
Acetic anhydride (18.9 L, 199 mol) was cooled to -10 °C and 70 % perchloric acid was added (2.8 L, 32.1 mol). The so obtained solution was cooled to -30 0C and the solution of compound of formula (II) - obtained in the previous step - in dichloromethane (26 L) was added at such rate to keep the temperature between -20 and -30 0C, then the reaction mixture was stirred at this temperature for 1 h. The mixture was diluted with dichloromethane of 0 0C (80 L) and poured into water (100 L) containing sodium acetate (2.65 kg, 32.4 mol). The organic layer was separated, washed with water (3x25 L), dried over sodium sulfate and concentrated under reduced pressure. The obtained yellow syrupy material was crystallized from isopropanol (40 L) to yield 7 kg of the title compound in solvate form, containing 5-10 % solvent. This material was dissolved in ethanol (60 L) at 60 0C, then warmed to 70 °C and ion-exchanged water (67 L) was added. Nitrogen was bubbled through the so obtained solution, which was kept at 70 0C for 14 h. The solvate-free crystalline product gradually precipitated from the solution. The crystals were filtered at 70 0C, washed with water of 70 0C and dried at 40 °C to yield 6.6 kg (64 %) of the title compound. The purity of the product was 99 % (according to HPLC).
Melting point: 184-186 °C.

Claims

What we claim is:
1. Industrial process for the synthesis of solvate-free 17α-acetoxy-llβ-[4-(N,N- dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione of formula (I) via ketal formation from 3-(ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)-diene-20-one of formula (VI), epoxide formation in position 5,10 of the obtained 3,3,20,20-bis(ethylene- dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)-diene of formula (V), reaction of the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-5,10-epoxy-19-norpregna-9(ll)-ene of formula (IV) with the Grignard reagent obtained from bromo-N,N-dimethyl-aniline, deprotection of the so formed 3,3,20,20-bis(ethylene-dioxy)-5α,17α-dihydroxy-llβ-[4-(N,N-dimethylamino)- phenyl]-19-norpregna-9(ll)-ene of formula (III), acetylation of the obtained llβ-[4-(N,N- dimethylamino)-phenyl]-17α-hydroxy-19-norpregna-4,9-diene-3,20-dione of formula (II) and finally liberation of the solvate-free form of the desired product, characterized by i) reacting 3-(ethylene-dioxy)-estra-5(10),9(ll)-diene-17-one of formula (X) with potassium acetilyde formed in situ in dry tetrahydrofuran by known method, ii) reacting the obtained 3-(ethylene-dioxy)-17α-ethynyl-17β-hydroxy-estra- 5(10),9(ll)-diene of formula (IX) with phenylsulfenyl chloride in dichloromethane in the presence of triethylamine and acetic acid, iii) reacting the obtained isomeric mixture of 3-(ethylene-dioxy)-21-(phenyl-sulfinyl)- 19-norpregna-5(10),9(l 1), 17(20),20-tetraene of formula (VIII) first with sodium methoxide in methanol, then with trimethyl phosphite, iv) reacting the obtained 3-(ethylene-dioxy)-17α-hydroxy-20-methoxy-19-norpregna- 5(10), 9(1 l),20-triene of formula (VII) with hydrogen chloride in methanol, then v) reacting the obtained 3-(ethylene-dioxy)-17α-hydroxy-19-norpregna-5(10),9(ll)- diene-20-one of formula (VI) with ethylene glycol in dichloromethane in the presence of trimethyl orthoformate and p-toluenesulfonic acid by known method, vi) reacting the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-19-norpregna- 5(10),9(ll)-diene of formula (V) with hydrogen peroxide in a mixture of pyridine and dichloromethane in the presence of hexachloroacetone by known method, vii) reacting the obtained 3,3,20,20-bis(ethylene-dioxy)-17α-hydroxy-5,10-epoxy-19- norpregn-9(ll)-ene of formula (IV), containing approximately a 1:1 mixture of 5α,10α- and 5β,10β-eρoxides, with a Grignard reagent obtained from 4-bromo-N,N-dimethyl-aniline in tetrahydrofuran in the presence of copper(I) chloride catalyst without separation of the isomers by known method, viii) reacting the obtained 3,3,20,20-bis(ethylene-dioxy)-5α,17α-dihydroxy-llβ-[4- (N,N-dimethylamino)-phenyl]-19-norpregn-9(ll)-ene of formula (III) with potassium hydrogensulfate in water by known method, ix) acetylation of the obtained llβ-[4-(N,N-dimethylamino)-phenyl]-17α-hydroxy-19- norpregn-4,9-diene-3,20-dione of formula (II) with acetic anhydride in the presence of perchloric acid by known method, finally x) liberation of the solvate-free compound of formula (I) from the obtained solvate containing compound of formula (I) in a 1 : 1 mixture of ethanol and water at 70 °C.
2. The process according to claim 1, characterized by using a chloroform solution of phenylsulfenyl chloride in step ii).
3. The process according to claim 1, characterized by carrying out the reaction with phenylsulfenyl chloride at 0-5 0C in step ii). ■
4. The process according to claim 1, characterized by carrying out the reaction with phenylsulfenyl chloride in the presence of 1.2 equivalent of acetic acid in step ii).
5. The process according to claim 1, characterized by carrying out the reaction with sodium methoxide and trimethyl phosphite at 62-64 0C in step iii).
6. 3-(Ethylene-dioxy)- 17α-hydroxy-20-methoxy~19-norpregna-5(10),9(l l),20-triene of formula (VII).
7. 3-(Ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(ll),17(20),20- tetraene of formula (VIII).
PCT/HU2007/000045 2006-06-14 2007-05-18 INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS Ceased WO2007144674A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2007258955A AU2007258955B2 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17alpha-acetoxy-11beta-[4-(N,N-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
PL07733862T PL2027140T3 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17 alpha -acetoxy-11 beta -[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
CA2653552A CA2653552C (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17.alpha.-acetoxy-11.beta.-[4-(n,n-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
SI200731232T SI2027140T1 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17 alpha -acetoxy-11 beta -s4-(n,n-dimethyl-amino)- phenylc-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
CN2007800219159A CN101466723B (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17a-acetoxy-11ss-[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
DK07733862.2T DK2027140T3 (en) 2006-06-14 2007-05-18 Industrial Process for the Synthesis of 17alpha-Acetoxy-11beta [4- (N, Ndimethyl-amino) -phenyl] -19-norpregna-4,9-diene-3,20-dione and the novel intermediates of the process
BRPI0713157-7A BRPI0713157A2 (en) 2006-06-14 2007-05-18 industrial process for the synthesis of 17a-acetoxy-11b- [4- (n, n-dimethyl-amino) -phenyl] -19-norpregna-4,9-diene-3,20-dione and new process intermediates of the process
JP2009514916A JP5274453B2 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17α-acetoxy-11β- [4- (N, N-dimethyl-amino) -phenyl] -19-norpregna-4,9-diene-3,20-dione and a new intermediate of the process body
EA200900015A EA015302B1 (en) 2006-06-14 2007-05-18 INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS
US12/303,160 US8110691B2 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
ES07733862T ES2409841T3 (en) 2006-06-14 2007-05-18 Industrial synthesis process of 17-alpha-acetoxy-11-beta- [4- (N, N-dimethyl-amino) -phenyl] -19-norpregna-4,9-dien- 3,20-diona and new intermediates of the procedure
RS20130179A RS52758B (en) 2006-06-14 2007-05-18 INDUSTRIAL PROCESS FOR 17ALFA-ACETOXY-11BETA SYNTHESIS [4- (N, N-DIMETHYL-AMINO) -Phenyl] -19 NORPREGNA-4,9-DIEN-3,20-DIONA AND NEW INTERMEDIATES IN THIS PROCESS
EP07733862A EP2027140B1 (en) 2006-06-14 2007-05-18 Industrial process for the synthesis of 17 alpha -acetoxy-11 beta -[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
MX2008015972A MX2008015972A (en) 2006-06-14 2007-05-18 INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17alpha-ACETOXY-11beta-[4-(N,N -DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS.
IL195253A IL195253A (en) 2006-06-14 2008-11-12 Industrial process for the synthesis of 17-alpha-acetoxy-11 beta- -[4-(n,n-dimethylamino)-phenyl]-19norpregna-4,9-diene-3,20-dione and intermediates o the process
NO20090196A NO341620B1 (en) 2006-06-14 2009-01-13 Industrial Process for the Synthesis of 17-Acetoxy-11- [4- (N, N-Dimethylamino) -phenyl] -19-norpregna-4,9-diene-3,20-dione and New Intermediates for the Process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0600491 2006-06-14
HU0600491A HU227112B1 (en) 2006-06-14 2006-06-14 Industrial process for the synthesis of 17alpha-acetoxy-11betha-[4-(n,n-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione and the new intermediates of the process

Publications (1)

Publication Number Publication Date
WO2007144674A1 true WO2007144674A1 (en) 2007-12-21

Family

ID=89986843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2007/000045 Ceased WO2007144674A1 (en) 2006-06-14 2007-05-18 INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS

Country Status (22)

Country Link
US (1) US8110691B2 (en)
EP (1) EP2027140B1 (en)
JP (1) JP5274453B2 (en)
CN (1) CN101466723B (en)
AR (1) AR061052A1 (en)
AU (1) AU2007258955B2 (en)
BR (1) BRPI0713157A2 (en)
CA (1) CA2653552C (en)
DK (1) DK2027140T3 (en)
EA (1) EA015302B1 (en)
ES (1) ES2409841T3 (en)
HU (1) HU227112B1 (en)
IL (1) IL195253A (en)
MX (1) MX2008015972A (en)
NO (1) NO341620B1 (en)
PL (1) PL2027140T3 (en)
PT (1) PT2027140E (en)
RS (1) RS52758B (en)
SI (1) SI2027140T1 (en)
UA (1) UA94269C2 (en)
WO (1) WO2007144674A1 (en)
ZA (1) ZA200809799B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014050106A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014050107A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014060888A1 (en) * 2012-10-18 2014-04-24 Lupin Limited Novel process and intermediate for preparation of ulipristal
WO2015049637A1 (en) 2013-10-01 2015-04-09 Richter Gedeon Nyrt. Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue
CN104530169A (en) * 2014-12-12 2015-04-22 徐州市华盛生物科技有限公司 Preparation method of ulipristal acetate and intermediate thereof
EP2767544A4 (en) * 2011-07-22 2015-07-08 Shanghai Cdymax Pharmaceuticals Co Ltd Amorphous substance of 17 -acetoxy-11 -(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and preparation method thereof
CN109053846A (en) * 2018-08-14 2018-12-21 台州仙琚药业有限公司 The method for preparing the double ketals of ulipristal acetate

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241722B (en) * 2010-05-12 2015-11-25 杭州容立医药科技有限公司 A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast
CN102372760A (en) * 2010-08-12 2012-03-14 杭州容立医药科技有限公司 Synthesis method of progesterone receptor regulating agent ulipristal
CN102477060B (en) * 2010-11-22 2014-08-13 华润紫竹药业有限公司 Novel steroid compound, and preparation method and application thereof
CN102516345B (en) * 2011-11-01 2014-11-26 上海优拓医药科技有限公司 Preparation method of ulipristal acetate and key intermediate thereof
CN102617692A (en) * 2011-01-31 2012-08-01 北京紫竹药业有限公司 Steroid compound and its preparation method and use
CN102295674B (en) * 2011-07-14 2013-04-10 四川大学 Method of acquiring high-purity 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4, 9-diene-3, 20-dione
CN102344478B (en) * 2011-07-22 2013-08-07 上海希迈医药科技有限公司 Crystal of 17 alpha-acetoxyl group-11 beta-(4-N, N-dimethylamino phenyl)-19-norpregna-4, 9- diene-3, 20- ketone and preparation method thereof
CN103193850A (en) * 2012-01-04 2013-07-10 北京紫竹药业有限公司 Novel crystal form of steroidal compound, and preparation method thereof
CN104628806A (en) * 2012-01-19 2015-05-20 华润紫竹药业有限公司 Steroid compound and preparation method and application thereof
CN103755765B (en) * 2012-04-17 2018-01-02 常州市第四制药厂有限公司 Polymorphic of CDB-2914 and preparation method thereof
CN102675395B (en) * 2012-04-17 2014-04-30 常州市第四制药厂有限公司 Polymorphic form of ulipristal acetate and preparation method thereof
CN102702296B (en) * 2012-06-19 2014-09-03 山东诚创医药技术开发有限公司 Preparation method of cyclo-3,20-bi(1, 2-ethidene acetal)-17alpha-hydroxyl-17beta-acetyl-estra-5(10),9(11)-diene-3-ketone
JP6200493B2 (en) 2012-09-28 2017-09-20 あすか製薬株式会社 Amorphous uripristal acetate
CN102875629B (en) * 2012-10-10 2014-11-19 苏州康润医药有限公司 Synthetic method of ulipristal acetate
CN102942612A (en) * 2012-10-30 2013-02-27 四川大学 Novel method for synthesizing ulipristal acetate
CN103804456B (en) * 2012-11-15 2017-08-04 上海创诺医药集团有限公司 CDB-2914 intermediate and preparation method thereof
CN103145787B (en) * 2012-12-25 2017-02-22 常州市亚邦医药研究所有限公司 Novel preparation method of ulipristal acetate key intermediate
CN103087140A (en) * 2013-03-04 2013-05-08 四川尚锐生物医药有限公司 Preparation method of ulipristal acetate polycrystal
CN103145788B (en) * 2013-03-25 2015-08-19 浙江仙琚制药股份有限公司 The preparation method of ulipristal acetate key intermediate
CN103755763A (en) * 2013-12-30 2014-04-30 烟台东诚生化股份有限公司 Preparation method of 17alpha-acetoxyl-11beta-(4-(N, N-dimethylamino)-phenyl)-19-norpregna-4, 9-diene-3, 20-diketone
CN106986911B (en) * 2017-03-23 2019-05-10 湖南玉新药业有限公司 The preparation method of dexamethasone key intermediate connection alkene sulfoxide object
CN106986908B (en) * 2017-03-23 2019-05-10 湖南玉新药业有限公司 The preparation method of betamethasone
CN108558982A (en) * 2018-05-21 2018-09-21 郑州泰丰制药有限公司 A kind of Novel acetate Ulipristal and its method for manufacturing
CN111349137A (en) * 2018-12-21 2020-06-30 北京启慧生物医药有限公司 Green synthesis method of ulipristal acetate intermediate and ulipristal acetate
CN110256519B (en) * 2019-05-23 2021-06-08 江苏联环药业股份有限公司 Method for preparing ulipristal acetate by one-pot method
CN119490551B (en) * 2024-11-15 2025-10-31 湖北葛店人福药业有限责任公司 Preparation method of dydrogesterone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041055A (en) * 1975-11-17 1977-08-09 The Upjohn Company Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
WO2004078709A2 (en) 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US6768014B2 (en) * 1999-12-29 2004-07-27 The United States Of America As Represented By The Department Of Health And Human Services PROCESS FOR PREPARING 17α-ACETOXY-11β-[4-N,N(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS , AND PROCESSES FOR PREPARING SUCH INTERMEDIATES
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
FR2854403B1 (en) * 2003-04-29 2008-07-11 Aventis Pharma Sa NOVEL METHOD AND INTERMEDIATES FOR THE PREPARATION OF 17-HALOGENES 19-NOR-STEROID COMPOUNDS
HUP0301332A3 (en) * 2003-05-14 2006-04-28 Richter Gedeon Vegyeszet New mono-and bismethylene steroid derivatives and process for their synthesis and pharmaceutical compositions containing them
ITMI20042001A1 (en) * 2004-10-21 2005-01-21 Ind Chimica Srl PROCESS FOR THE PREPARATION OF 21-STEROID HYDROXIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION IN POSITION C-21

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041055A (en) * 1975-11-17 1977-08-09 The Upjohn Company Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
WO2004078709A2 (en) 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEROIDS, vol. 63, 1998, pages 50 - 57
VANRHEENEN, VERLAN ET AL: "New synthesis of cortico steroids from 17-keto steroids: application and stereochemical study of the unsaturated sulfoxide-sulfenate rearrangement", JOURNAL OF ORGANIC CHEMISTRY , 44(9), 1582-4 CODEN: JOCEAH; ISSN: 0022-3263, 1979, XP002457880 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767544A4 (en) * 2011-07-22 2015-07-08 Shanghai Cdymax Pharmaceuticals Co Ltd Amorphous substance of 17 -acetoxy-11 -(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and preparation method thereof
WO2014050106A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014050107A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
US9643994B2 (en) 2012-09-28 2017-05-09 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
US9643993B2 (en) 2012-09-28 2017-05-09 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014060888A1 (en) * 2012-10-18 2014-04-24 Lupin Limited Novel process and intermediate for preparation of ulipristal
WO2015049637A1 (en) 2013-10-01 2015-04-09 Richter Gedeon Nyrt. Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue
US9676814B2 (en) 2013-10-01 2017-06-13 Richter Gedeon Nyrt. Industrial process for the synthesis of ulipristal acetate and its 4′-acetyl analogue
CN104530169A (en) * 2014-12-12 2015-04-22 徐州市华盛生物科技有限公司 Preparation method of ulipristal acetate and intermediate thereof
CN109053846A (en) * 2018-08-14 2018-12-21 台州仙琚药业有限公司 The method for preparing the double ketals of ulipristal acetate
CN109053846B (en) * 2018-08-14 2020-01-07 台州仙琚药业有限公司 Method for preparing ulipristal bisketal acetate

Also Published As

Publication number Publication date
JP2009539964A (en) 2009-11-19
CA2653552A1 (en) 2007-12-21
EA015302B1 (en) 2011-06-30
HUP0600491A2 (en) 2008-02-28
RS52758B (en) 2013-08-30
AU2007258955A1 (en) 2007-12-21
SI2027140T1 (en) 2013-07-31
AU2007258955B2 (en) 2012-09-20
CA2653552C (en) 2013-04-23
BRPI0713157A2 (en) 2012-04-03
PL2027140T3 (en) 2013-09-30
UA94269C2 (en) 2011-04-26
PT2027140E (en) 2013-06-04
NO20090196L (en) 2009-03-10
ZA200809799B (en) 2009-11-25
US20090187032A1 (en) 2009-07-23
EP2027140B1 (en) 2013-03-13
EA200900015A1 (en) 2009-04-28
HU227112B1 (en) 2010-07-28
JP5274453B2 (en) 2013-08-28
US8110691B2 (en) 2012-02-07
DK2027140T3 (en) 2013-06-03
AR061052A1 (en) 2008-07-30
ES2409841T3 (en) 2013-06-28
EP2027140A1 (en) 2009-02-25
NO341620B1 (en) 2017-12-11
CN101466723B (en) 2011-11-02
IL195253A (en) 2011-11-30
HU0600491D0 (en) 2006-08-28
IL195253A0 (en) 2009-08-03
MX2008015972A (en) 2009-01-12
CN101466723A (en) 2009-06-24

Similar Documents

Publication Publication Date Title
EP2027140B1 (en) Industrial process for the synthesis of 17 alpha -acetoxy-11 beta -[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process
EP2774933B1 (en) Ulipristal acetate preparation method and intermediate thereof
EP0263569B1 (en) 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives.
HUP0000901A2 (en) 16-Hydroxy-11-(substituted phenyl)estra-4,9-diene derivatives, process for their production and pharmaceutical preparations containing them
JP2721002B2 (en) Improvements in the synthesis of 6-methylene derivatives of androsta-1,4-diene-3,17-dione
JP3037427B2 (en) Starting compounds for producing calcitriol and its derivatives, methods for producing these starting compounds and intermediates for this method
EP1242444B1 (en) Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
JP2016533347A (en) Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue
US7268241B2 (en) Method for the production of 4-(17$g(a)-methyl substituted 3-oxoestra-4 9-dien-11$g(b)-yl)benzaldehyd-(1e or 1z)-oximes
CA2427632C (en) Process for the production of 4-(17.alpha.-substituted-3-oxoestra-4,9-dien-11.beta.-yl)benzaldehyde-(1e or 1z)-oximes
US20060111332A1 (en) Process and intermediates to prepare17beta-hydroxy-7alpha-methyl-19-nor-17alpha-pregn -5(10)-en-20-yn-3-one
EP0115965A2 (en) Process for converting 17-keto-steroids to 16-beta-methyl-17-keto-steroids
CS271482B2 (en) Method of 11-beta, 21-dihydroxy-16-alpha, 17-butylidenbis oxypregna-1,4-diene-3,20-dione production

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780021915.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07733862

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007258955

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2653552

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007733862

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12303160

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2007258955

Country of ref document: AU

Date of ref document: 20070518

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015972

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009514916

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 98/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200900015

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0713157

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081215

WWE Wipo information: entry into national phase

Ref document number: P-2013/0179

Country of ref document: RS